ALLERGAN'S ALPHAGAN RECEIVES U.K. APPROVAL.IRVINE, Calif.--(BW HealthWire)--March 24, 1997--Allergan, Inc. (NYSE NYSE See: New York Stock Exchange :AGN AGN Again (Amateur Radio) AGN Active Galactic Nucleus AGN Acute Glomerulonephritis AGN Accountants Global Network AGN Air Gabon (ICAO code) ) today announced that it has received clearance from the Medicines Control Agency to market ALPHAGAN(r)(brimonidine) in the United Kingdom for the treatment of open-angle glaucoma o·pen-an·gle glaucoma n. Primary glaucoma in which the aqueous humor has free access to the trabecular reticulum. Also called simple glaucoma. and ocular hypertension. Allergan will seek approval to market ALPHAGAN(r) in the balance of the European community through the mutual recognition filing process. ALPHAGAN(r) is a selective alpha2 agonist that significantly lowers intraocular pressure intraocular pressure n. The pressure of the intraocular fluid within the eye. intraocular pressure (in´tr with minimal effects on cardiovascular and pulmonary parameters. Its unique dual mechanism of action lowers intraocular pressure by reducing aqueous humor aqueous humor n. The clear, watery fluid circulating in the chamber of the eye between the cornea and the lens. Aqueous humor production and increasing uveoscleral outflow. Glaucoma, an eye disease commonly characterized by excessive intraocular pressure, is a leading cause of blindness in the world. "ALPHAGAN(r) has been one of the top growth products in our ophthalmic pharmaceutical business," said Allergan Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. William C. Shepherd. "Physician acceptance and early sales trends in the U.S. have exceeded our expectations." In September 1996, Allergan received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval to market ALPHAGAN(r) in the United States for the treatment of open-angle glaucoma and ocular hypertension. On March 13, 1997, Allergan received FDA approval to market ALPHAGAN(r) in the United States for the prevention of post-operative intraocular pressure elevations in patients undergoing argon argon (är`gŏn) [Gr.,=inert], gaseous chemical element; symbol Ar; at. no. 18; at. wt. 39.948; m.p. −189.2°C;; b.p. −185.7°C;; density 1.784 grams per liter at STP; valence 0. laser trabeculoplasty. On March 11, 1997, Allergan received approval from the Ministerio da Saude to market ALPHAGAN(r) in Brazil for these same indications. Any of the above statements that refer to the Company's estimated or anticipated future results are forward-looking and reflect the Company's current analysis of existing trends and information. Actual results may differ from current expectations based on a number of factors affecting Allergan's businesses including competitive conditions and changing market conditions, the timing and uncertainty of results of both research and regulatory processes and performance, including patient acceptance of new products. These forward-looking statements represent the Company's judgment only as of the date of this press release. Actual results could differ materially from those projected in this release. As a result, the reader is cautioned not to rely on these forward-looking statements. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Allergan, Inc., headquartered in Irvine, California, is a technology-driven, global health care company, focused on specialty pharmaceutical products for specific disease areas that deliver value to customers, satisfy unmet medical needs and improve patients' lives. Contact: Jeff D'Eliscu 714/246-4636 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion